Neuphoria Therapeutics Gets $15M Milestone Payment from Merck
Neuphoria Therapeutics (Nasdaq: NEUP) will receive a $15 million milestone payment from Merck due to the initiation of a...
Bio-Path Holdings Announces Promising Phase 1/1b AML Trial Results
Bio-Path Holdings announced positive findings from its Phase 1/1b clinical trial of BP1002, a drug designed to treat refractory/relapsed...
Updated Phase 2 Agent-797 Gastric Cancer Data at AACR IO
MiNK Therapeutics will present interim Phase 2 data on AgenT-797 combined with botensilimab and balstilimab for refractory gastric cancer...
Orchestra Biomed Announces Favorable AVIM Therapy Data for Heart Failure at THT 2025
Orchestra BioMed Holdings announced positive data from a retrospective analysis of its MODERATO II study, demonstrating that atrioventricular interval...
Windtree Therapeutics Presents Late-Breaking Istaroxime Data at Heart Failure Conference
Windtree Therapeutics announced a presentation on its drug istaroxime at the Technology and Heart Failure Therapeutics Conference. The presentation...
Escharex’s Pivotal Trial for Venous Leg Ulcers
MediWound has launched VALUE, a pivotal Phase III trial for EscharEx®, its enzymatic treatment for venous leg ulcers (VLUs)....
Aptose’s Triple Drug AML Therapy Shows Promise in Phase 1/2 Trial
Aptose Biosciences reported promising early results from its Phase 1/2 TUSCANY trial, testing a triplet therapy of tuspetinib, venetoclax,...
Ati-2138: Potent, Selective Inhibitor of ITK and JAK3
Aclaris Therapeutics announced the publication of research on ATI-2138, a novel dual inhibitor of ITK and JAK3, currently in...
Tasso’s Patient-Centric Dried Blood Spot Technology
Tasso, a leader in patient-centric blood collection, launched its next-generation dried blood spot (DBS) sample collection system. This system...
Kairos Pharma and Huntsman Cancer Institute for ENV105 Phase 2 Trial
Kairos Pharma (NYSE American: KAPA) is expanding its Phase 2 clinical trial for ENV105, a drug targeting castrate-resistant prostate...